Annual CFO
-$68.44 M
-$24.91 M-57.23%
December 31, 2023
Summary
- As of February 22, 2025, ATXS annual cash flow from operations is -$68.44 million, with the most recent change of -$24.91 million (-57.23%) on December 31, 2023.
- During the last 3 years, ATXS annual CFO has fallen by -$35.96 million (-110.70%).
- ATXS annual CFO is now -318.21% below its all-time high of -$16.37 million, reached on December 31, 2013.
Performance
ATXS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$27.96 M
-$11.17 M-66.55%
September 30, 2024
Summary
- As of February 22, 2025, ATXS quarterly cash flow from operations is -$27.96 million, with the most recent change of -$11.17 million (-66.55%) on September 30, 2024.
- Over the past year, ATXS quarterly CFO has dropped by -$13.71 million (-96.14%).
- ATXS quarterly CFO is now -507.54% below its all-time high of -$4.60 million, reached on March 31, 2014.
Performance
ATXS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$94.09 M
-$13.71 M-17.05%
September 30, 2024
Summary
- As of February 22, 2025, ATXS TTM cash flow from operations is -$94.09 million, with the most recent change of -$13.71 million (-17.05%) on September 30, 2024.
- Over the past year, ATXS TTM CFO has dropped by -$45.22 million (-92.52%).
- ATXS TTM CFO is now -1944.06% below its all-time high of -$4.60 million, reached on March 31, 2014.
Performance
ATXS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ATXS Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -57.2% | -96.1% | -92.5% |
| 3 y3 years | -110.7% | -96.1% | -92.5% |
| 5 y5 years | -191.7% | -96.1% | -92.5% |
ATXS Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -127.0% | at low | -344.9% | +7.5% | -212.1% | at low |
| 5 y | 5-year | -157.6% | at low | -344.9% | +7.5% | -254.1% | at low |
| alltime | all time | -318.2% | at low | -507.5% | +7.5% | -1944.1% | at low |
Astria Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$27.96 M(+66.5%) | -$94.09 M(+17.1%) |
| Jun 2024 | - | -$16.79 M(-12.1%) | -$80.38 M(+8.2%) |
| Mar 2024 | - | -$19.09 M(-36.9%) | -$74.29 M(+8.5%) |
| Dec 2023 | -$68.44 M(+57.2%) | -$30.24 M(+112.1%) | -$68.44 M(+40.1%) |
| Sep 2023 | - | -$14.26 M(+33.3%) | -$48.87 M(+8.9%) |
| Jun 2023 | - | -$10.70 M(-19.3%) | -$44.86 M(+1.4%) |
| Mar 2023 | - | -$13.25 M(+24.3%) | -$44.23 M(+1.6%) |
| Dec 2022 | -$43.53 M(+44.4%) | -$10.66 M(+4.0%) | -$43.53 M(+11.2%) |
| Sep 2022 | - | -$10.25 M(+1.9%) | -$39.16 M(+6.8%) |
| Jun 2022 | - | -$10.06 M(-19.9%) | -$36.66 M(+7.8%) |
| Mar 2022 | - | -$12.56 M(+99.8%) | -$33.99 M(+12.7%) |
| Dec 2021 | -$30.15 M(-7.2%) | -$6.29 M(-18.9%) | -$30.15 M(-5.6%) |
| Sep 2021 | - | -$7.75 M(+4.7%) | -$31.93 M(-6.5%) |
| Jun 2021 | - | -$7.40 M(-15.1%) | -$34.15 M(-0.2%) |
| Mar 2021 | - | -$8.72 M(+8.1%) | -$34.21 M(+5.3%) |
| Dec 2020 | -$32.48 M(+22.3%) | -$8.06 M(-19.1%) | -$32.48 M(+0.9%) |
| Sep 2020 | - | -$9.97 M(+33.5%) | -$32.19 M(+12.2%) |
| Jun 2020 | - | -$7.47 M(+6.8%) | -$28.70 M(+6.4%) |
| Mar 2020 | - | -$6.99 M(-10.1%) | -$26.97 M(+1.5%) |
| Dec 2019 | -$26.57 M | -$7.77 M(+20.0%) | -$26.57 M(+10.4%) |
| Sep 2019 | - | -$6.47 M(+12.8%) | -$24.07 M(+3.0%) |
| Jun 2019 | - | -$5.74 M(-12.9%) | -$23.37 M(+0.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$6.59 M(+25.0%) | -$23.23 M(-1.0%) |
| Dec 2018 | -$23.46 M(-12.6%) | -$5.27 M(-8.8%) | -$23.46 M(-1.5%) |
| Sep 2018 | - | -$5.78 M(+3.1%) | -$23.83 M(-6.4%) |
| Jun 2018 | - | -$5.60 M(-17.8%) | -$25.47 M(-0.3%) |
| Mar 2018 | - | -$6.82 M(+21.0%) | -$25.55 M(-4.8%) |
| Dec 2017 | -$26.84 M(-18.3%) | -$5.64 M(-24.0%) | -$26.84 M(-8.0%) |
| Sep 2017 | - | -$7.41 M(+30.5%) | -$29.18 M(+1.8%) |
| Jun 2017 | - | -$5.68 M(-29.9%) | -$28.67 M(-9.9%) |
| Mar 2017 | - | -$8.11 M(+1.5%) | -$31.82 M(-3.2%) |
| Dec 2016 | -$32.86 M(+10.3%) | -$7.98 M(+15.7%) | -$32.86 M(-2.3%) |
| Sep 2016 | - | -$6.90 M(-21.9%) | -$33.62 M(-2.7%) |
| Jun 2016 | - | -$8.83 M(-3.5%) | -$34.55 M(+8.9%) |
| Mar 2016 | - | -$9.15 M(+4.6%) | -$31.71 M(+6.4%) |
| Dec 2015 | -$29.79 M(+46.0%) | -$8.74 M(+11.7%) | -$29.79 M(+10.5%) |
| Sep 2015 | - | -$7.83 M(+30.6%) | -$26.97 M(+13.0%) |
| Jun 2015 | - | -$6.00 M(-17.1%) | -$23.87 M(+3.6%) |
| Mar 2015 | - | -$7.23 M(+22.1%) | -$23.04 M(+12.9%) |
| Dec 2014 | -$20.41 M(+24.7%) | -$5.92 M(+25.2%) | -$20.41 M(+40.9%) |
| Sep 2014 | - | -$4.73 M(-8.4%) | -$14.49 M(+48.4%) |
| Jun 2014 | - | -$5.16 M(+12.1%) | -$9.76 M(+112.1%) |
| Mar 2014 | - | -$4.60 M | -$4.60 M |
| Dec 2013 | -$16.37 M | - | - |
FAQ
- What is Astria Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Astria Therapeutics?
- What is Astria Therapeutics annual CFO year-on-year change?
- What is Astria Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Astria Therapeutics?
- What is Astria Therapeutics quarterly CFO year-on-year change?
- What is Astria Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Astria Therapeutics?
- What is Astria Therapeutics TTM CFO year-on-year change?
What is Astria Therapeutics annual cash flow from operations?
The current annual CFO of ATXS is -$68.44 M
What is the all time high annual CFO for Astria Therapeutics?
Astria Therapeutics all-time high annual cash flow from operations is -$16.37 M
What is Astria Therapeutics annual CFO year-on-year change?
Over the past year, ATXS annual cash flow from operations has changed by -$24.91 M (-57.23%)
What is Astria Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ATXS is -$27.96 M
What is the all time high quarterly CFO for Astria Therapeutics?
Astria Therapeutics all-time high quarterly cash flow from operations is -$4.60 M
What is Astria Therapeutics quarterly CFO year-on-year change?
Over the past year, ATXS quarterly cash flow from operations has changed by -$13.71 M (-96.14%)
What is Astria Therapeutics TTM cash flow from operations?
The current TTM CFO of ATXS is -$94.09 M
What is the all time high TTM CFO for Astria Therapeutics?
Astria Therapeutics all-time high TTM cash flow from operations is -$4.60 M
What is Astria Therapeutics TTM CFO year-on-year change?
Over the past year, ATXS TTM cash flow from operations has changed by -$45.22 M (-92.52%)